The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Evaluation of No Evidence of Disease Activity in a 7-Year Longitudinal Multiple Sclerosis Cohort
Abstract
IMPORTANCE: With multiple and increasingly effective therapies for relapsing forms of multiple sclerosis (MS), disease-free status or no evidence of disease activity (NEDA) has become a treatment goal and a new outcome measure. However, the persistence of NEDA over time and its predictive power for long-term prognosis are unknown. OBJECTIVE: To investigate NEDA during 7 years as measured by relapses, disability progression, and yearly magnetic resonance imaging (MRI). DESIGN, SETTING, AND PARTICIPANTS: Patients were selected from the 2200-patient Comprehensive Longitudinal Investigation of Multiple Sclerosis at Brigham and Women's Hospital (CLIMB) cohort study. Patients were required to have an initial diagnosis of clinically isolated syndrome or relapsing-remitting MS and a minimum of 7 years of prospective follow-up that included yearly brain MRI and biannual clinical visits (n = 219). Patients were analyzed independent of disease-modifying therapy. Patients were classified as having early (recent-onset) MS if they were 5 years or less from their first MS symptom at enrollment or otherwise considered to have established MS (>5 years from onset). MAIN OUTCOMES AND MEASURES: NEDA was defined as a composite that consisted of absence of relapses, no sustained Expanded Disability Status Scale score progression, and no new or enlarging T2 or T1 gadolinium-enhancing lesions on annual MRI. Relapses, progression, and MRI changes were also investigated as individual outcomes. RESULTS: A total of 99 of 215 patients (46.0%) had NEDA for clinical and MRI measures at 1 year, but only 17 of 216 (7.9%) maintained NEDA status after 7 years. No differences were found in NEDA status between patients with early vs established MS. A dissociation was found between clinical and MRI disease activity. Each year, 30.6% (64 of 209) to 42.9% (93 of 217) of the cohort had evidence of either clinical or MRI disease activity but not both. NEDA at 2 years had a positive predictive value of 78.3% for no progression (Expanded Disability Status Scale score change ≤0.5) at 7 years. Only minor improvement was found in the positive predictive values with additional follow-up of 1 to 3 years. CONCLUSIONS AND RELEVANCE: NEDA is difficult to sustain long term even with treatment. NEDA status at 2 years may be optimal in terms of prognostic value in the longer term. Our results provide a basis for investigating NEDA as an outcome measure and treatment goal and for evaluating the effect of new MS drugs on NEDA.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
McDonald, W. I., Compston, A., Edan, G., Goodkin, D., Hartung, H., Lublin, F. D., McFarland, H. F., Paty, D. W., Polman, C. H., Reingold, S. C., et al. (2001) · Annals of Neurology · doi:10.1002/ana.1032 · Cited by 6,969
Confavreux, C. (2003) · Brain · doi:10.1093/brain/awg081 · Cited by 996
Fisniku, L. K., Brex, P. A., Altmann, D. R., Miszkiel, K. A., Benton, C. E., Lanyon, R., Thompson, A. J., & Miller, D. H. (2008) · Brain · doi:10.1093/brain/awm329 · Cited by 897
A longitudinal study of abnormalities on MRI and disability from multiple sclerosis
Brex, P. A., Ciccarelli, O., O'Riordan, J. I., Sailer, M., Thompson, A. J., & Miller, D. H. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa011341 · Cited by 861
The clinico-radiological paradox in multiple sclerosis revisited
Barkhof, F. (2002) · Current Opinion in Neurology · doi:10.1097/00019052-200206000-00003 · Cited by 726
Scalfari, A., Neuhaus, A., Degenhardt, A., Rice, G. P., Muraro, P. A., Daumer, M., & Ebers, G. C. (2010) · Brain · doi:10.1093/brain/awq118 · Cited by 711
Gray matter atrophy in multiple sclerosis: A longitudinal study
Fisher, E., Lee, J., Nakamura, K., & Rudick, R. A. (2008) · Annals of Neurology · doi:10.1002/ana.21436 · Cited by 670
Evidence for a two-stage disability progression in multiple sclerosis
Leray, E., Yaouanq, J., Le Page, E., Coustans, M., Laplaud, D., Oger, J., & Edan, G. (2010) · Brain · doi:10.1093/brain/awq076 · Cited by 596
Havrdova, E., Galetta, S., Hutchinson, M., Stefoski, D., Bates, D., Polman, C. H., O'Connor, P. W., Giovannoni, G., Phillips, J. T., Lublin, F. D., et al. (2009) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70021-3 · Cited by 471
The measurement and clinical relevance of brain atrophy in multiple sclerosis
Bermel, R. A., & Bakshi, R. (2006) · The Lancet Neurology · doi:10.1016/s1474-4422(06)70349-0 · Cited by 456
Giovannoni, G., Cook, S., Rammohan, K., Rieckmann, P., Sørensen, P. S., Vermersch, P., Hamlett, A., Viglietta, V., & Greenberg, S. (2011) · The Lancet Neurology · doi:10.1016/s1474-4422(11)70023-0 · Cited by 252
Langer-Gould, A., Popat, R. A., Huang, S. M., Cobb, K., Fontoura, P., Gould, M. K., & Nelson, L. M. (2006) · Archives of Neurology · doi:10.1001/archneur.63.12.1686 · Cited by 229
Impact of multiple sclerosis relapses on progression diminishes with time
Tremlett, H., Yousefi, M., Devonshire, V., Rieckmann, P., & Zhao, Y. (2009) · Neurology · doi:10.1212/wnl.0b013e3181c1e44f · Cited by 221
Khatri, B., Barkhof, F., Comi, G., Hartung, H.-P., Kappos, L., Montalban, X., Pelletier, J., Stites, T., Wu, S., Holdbrook, F., et al. (2011) · The Lancet Neurology · doi:10.1016/s1474-4422(11)70099-0 · Cited by 218
MRI in multiple sclerosis: correlation with expanded disability status scale (EDSS)
Barkhof, F. (1999) · Multiple Sclerosis Journal · doi:10.1177/135245859900500415 · Cited by 215
MRI T2 lesion burden in multiple sclerosis: A plateauing relationship with clinical disability
Li, D. K. B., Held, U., Petkau, J., Daumer, M., Barkhof, F., Fazekas, F., Frank, J. A., Kappos, L., Miller, D. H., Simon, J. H., et al. (2006) · Neurology · doi:10.1212/01.wnl.0000210506.00078.5c · Cited by 208
Menzin, J., Caon, C., Nichols, C., White, L. A., Friedman, M., & Pill, M. W. (2013) · Journal of Managed Care Pharmacy · doi:10.18553/jmcp.2013.19.s1.s24 · Cited by 204
Randomized study combining interferon and glatiramer acetate in multiple sclerosis
Lublin, F. D., Cofield, S. S., Cutter, G. R., Conwit, R., Narayana, P. A., Nelson, F., Salter, A. R., Gustafson, T., Wolinsky, J. S., & for the CombiRx Investigators (2013) · Annals of Neurology · doi:10.1002/ana.23863 · Cited by 203
Quantitative functional measures in MS: What is a reliable change?
Schwid, S. R., Goodman, A. D., McDermott, M. P., Bever, C. F., & Cook, S. D. (2002) · Neurology · doi:10.1212/wnl.58.8.1294 · Cited by 181
Predictors of long‐term outcome in multiple sclerosis patients treated with interferon beta
Bermel, R. A., You, X., Foulds, P., Hyde, R., Simon, J. H., Fisher, E., & Rudick, R. A. (2013) · Annals of Neurology · doi:10.1002/ana.23758 · Cited by 180
Black holes in multiple sclerosis: definition, evolution, and clinical correlations
Sahraian, M. A., Radue, E. W., Haller, S., & Kappos, L. (2009) · Acta Neurologica Scandinavica · doi:10.1111/j.1600-0404.2009.01221.x · Cited by 176
Disability in multiple sclerosis: A reference for patients and clinicians
Kister, I., Chamot, E., Salter, A. R., Cutter, G. R., Bacon, T. E., & Herbert, J. (2013) · Neurology · doi:10.1212/wnl.0b013e3182872855 · Cited by 176
Sanfilipo, M. P., Benedict, R. H. B., Sharma, J., Weinstock-Guttman, B., & Bakshi, R. (2005) · NeuroImage · doi:10.1016/j.neuroimage.2005.03.008 · Cited by 175
Timed 25-Foot Walk: Direct evidence that improving 20% or greater is clinically meaningful in MS
Hobart, J., Blight, A. R., Goodman, A., Lynn, F., & Putzki, N. (2013) · Neurology · doi:10.1212/wnl.0b013e31828cf7f3 · Cited by 168
Longitudinal follow-up of “benign” multiple sclerosis at 20 years
Sayao, A., Devonshire, V. A., & Tremlett, H. L. (2007) · Neurology · doi:10.1212/01.wnl.0000253185.03943.66 · Cited by 158
Gauthier, S. A., Glanz, B. I., Mandel, M., & Weiner, H. L. (2006) · Autoimmunity Reviews · doi:10.1016/j.autrev.2006.02.012 · Cited by 153
Self-citationBevan, C. J., & Cree, B. (2014) · JAMA Neurology · doi:10.1001/jamaneurol.2013.5486 · Cited by 144
Freedom from disease activity in multiple sclerosis
Havrdová, E., Galetta, S. L., Stefoski, D., & Comı, G. (2010) · Neurology · doi:10.1212/wnl.0b013e3181dbb51c · Cited by 140
One‐year MRI scan predicts clinical response to interferon beta in multiple sclerosis
Prosperini, L., Gallo, V., Petsas, N., Borriello, G., & Pozzilli, C. (2009) · European Journal of Neurology · doi:10.1111/j.1468-1331.2009.02708.x · Cited by 128
Combined MRI lesions and relapses as a surrogate for disability in multiple sclerosis
Sormani, M. P., Li, D. K., Bruzzi, P., Stubinski, B., Cornelisse, P., Rocak, S., & Stefano, N. D. (2011) · Neurology · doi:10.1212/wnl.0b013e31823648b9 · Cited by 114
Defining and scoring response to IFN-β in multiple sclerosis
Sormani, M. P., & Stefano, N. D. (2013) · Nature Reviews Neurology · doi:10.1038/nrneurol.2013.146 · Cited by 114
Disease activity free status in MS
LUBLIN, F. D. (2011) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2011.08.001 · Cited by 51
Clinically benign multiple sclerosis despite large T2 lesion load: Can we explain this paradox?
Strasser‐Fuchs, S., Enzinger, C., Ropele, S., Wallner-Blazek, M., & Fazekas, F. (2007) · Multiple Sclerosis Journal · doi:10.1177/1352458507082354 · Cited by 49
Bosma, L. V., Kragt, J. J., Polman, C. H., & Uitdehaag, B. M. J. (2012) · Multiple Sclerosis Journal · doi:10.1177/1352458512454346 · Cited by 36
LONGITUDINAL FOLLOW-UP OF “BENIGN” MULTIPLE SCLEROSIS AT 20 YEARS
Amato, M. P., & Stefano, N. D. (2007) · Neurology · doi:10.1212/01.wnl.0000281903.32474.15 · Cited by 10
Cited by
Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis
Hauser, S. L., Bar-Or, A., Comi, G., Giovannoni, G., Hartung, H.-P., Hemmer, B., Lublin, F., Montalban, X., Rammohan, K. W., Selmaj, K., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1601277 · Cited by 2,021
Filippi, M., Bar-Or, A., Piehl, F., Preziosa, P., Solari, A., Vukusic, S., & Rocca, M. A. (2018) · Nature Reviews Disease Primers · doi:10.1038/s41572-018-0041-4 · Cited by 1,562
Multiple Sclerosis: Mechanisms and Immunotherapy
Baecher-Allan, C., Kaskow, B. J., & Weiner, H. L. (2018) · Neuron · doi:10.1016/j.neuron.2018.01.021 · Cited by 938
Self-citationBenedict, R. H., DeLuca, J., Phillips, G., LaRocca, N., Hudson, L. D., Rudick, R., & Multiple Sclerosis Outcome Assessments Consortium (2017) · Multiple Sclerosis Journal · doi:10.1177/1352458517690821 · Cited by 839
ECTRIMS/EAN Guideline on the pharmacological treatment of people with multiple sclerosis
Montalban, X., Gold, R., Thompson, A. J., Otero-Romero, S., Amato, M. P., Chandraratna, D., Clanet, M., Comi, G., Derfuss, T., Fazekas, F., et al. (2018) · Multiple Sclerosis Journal · doi:10.1177/1352458517751049 · Cited by 712
Metadata
- Authors
- Rotstein, D. L., Healy, B. C., Malik, M. T., Chitnis, T., & Weiner, H. L.
- Venue
- JAMA Neurology
- Publisher
- American Medical Association (AMA)
- Published
- 2015-02-01
- Volume
- 72
- Issue
- 2
- Pages
- 152
- ISSN
- 2168-6149 (ISSN-L)
- OpenAlex
- W2143771994
- Cited by
- 418
- References
- 35
- FWCI
- 27.04
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.